Work

The evolving treatment landscape of advanced urothelial carcinoma

Year: 2021

Type: article

Abstract: PURPOSE OF REVIEW: Bladder cancer is the 10th most common cancer in the world and the 6th most common cancer among men. In the past few years, several new agents have been approved for the treatment of urothelial tumors. In this paper, we review the evolving treatment landscape of advanced urothelial carcinoma (UC). RECENT FINDINGS: Since 2016, the Food and Drug Administration (FDA) has approved five immunotherapies targeting programmed cell death 1/programmed cell death 1 legend, an antinectin-4 antibody drug conjugate (ADC), and a fibroblast growth factor receptor (FGFR) inhibitor for the treatment of patients with advanced UC. Moreover, there are multiple targeted agents, immune checkpoint inhibitors (ICI), ADCs, and their combinations currently being tested in clinical studies with the goal of obtaining FDA approval. SUMMARY: Precision oncology efforts continue to advance our understanding of the UC biology and transform the existing treatment paradigms. An enlarging arsenal of treatment options promises further personalization of UC therapy.

Source: Current Opinion in Oncology

DOI: 10.1097/cco.0000000000000722

Authors: Alexander Y. Andreev-Drakhlin, Goar Egoryan, Amishi Y. Shah, Pavlos Msaouel, Omar Alhalabi, Jianjun Gao

Institutions: The University of Texas MD Anderson Cancer Center, St. Francis Hospital, Amita Health

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Andrew Sabin Family Foundation, National Institutes of Health, University of Texas MD Anderson Cancer Center